Molecular and cellular pathways of neurodegeneration in motor neurone disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 8, 2005, Pages 1046-1057

  Shaw, Pamela J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; DYNACTIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; SYNAPTOBREVIN; VASCULOTROPIN;

ALSIN GENE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; CELL DEATH; CELL SPECIFICITY; EXCITOTOXICITY; GENE; GENE LOCUS; GENE MUTATION; HUMAN; MISSENSE MUTATION; MITOCHONDRION; MOTONEURON; MOTOR NEURON DISEASE; NERVE DEGENERATION; NERVE FIBER TRANSPORT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SENATAXIN GENE;

EID: 23144448320     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.048652     Document Type: Review

References (163)

1. Maasilta P, Jokelainen M, Loytonen M, et al. Mortality from amyotrophic lateral sclerosis in Finland, 1986-1995. Acta Neurol Scand 2001;104:232-5.
2. Rowland LP. Clinical aspects of sporadic ALS/MND. In: Shaw PJ, Strong MJ, eds. Blue book of practical neurology: motor neuron disorders. Philadelphia: Heinemann, 2003:111-44.
3. Charcot JM, Joffroy A. Deux cas d'atrophie musculaire progressive avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere. Arch Physiol Neurol Pathol 1869;2:744.
4. Ince PG, Tomkins J, Slade JY, et al. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology or five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J Neuropatnol Exp Neurol 1998;57:895-904.
5. Mannen T, Iwata M, Toyokura Y, et al. Preservation of a certain motoneurone group of the sacral cord in amyotrophic lateral sclerosis: its clinical significance. J Neurol Neurosurg Psychiatry 1977;40:464-9.
6. del Aguila MA, Longstreth WT, McGuire V, et al. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003;60:813-19.
7. Turner MR, Parton MJ, Shaw CE, et al. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry 2003;74:995-7.
8. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-9.
9. Wharton SP. Pathology of motor neuron disorders. In: Shaw PJ Strong MJ, eds. Blue books of practical neurology: motor neuron disorders. Philadelphia: Butterworth-Heinemann, 2003:17-50.
10. Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 1981;104:217-47.
11. Massman PJ, Sims J, Cooke N, et al. Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1996;61:450-5.
12. Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;364:362.
13. Andersen PM, Sims KB, Xin WW, et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:62-73.
14. http://www.alsod.org.
15. Okado-Matsumoto A, Fridovich I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem 2001;276:38388-93.
16. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723-49.
17. Andersen PM, Forsgren L, Binzer M, et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996;119:1153-72.
18. Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997;41:210-21.
19. Kunst CB, Messer L, Gordon J, et al. Genetic mapping of a mouse modifier gene that can prevent ALS onset. Genomics 2000;70:181-9.
20. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-16.
21. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994;264:1772-5.
22. Bruijn LI, Cleveland DW. Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Neuropathol Appl Neurobiol 1996;22:373-87.
23. Nagai M, Aoki M, Miyoshi I, et al. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci 2001;21:9240-54.
24. Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 2002;99:1604-9.
25. Cookson MR, Menzies FM, Manning P, et al. Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:75-85.
26. Pasinelli P, Borchelt DR, Houseweart MK, et al. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA 1998;95:15763-8.
27. Roy J, Minotti S, Dong L, et al. Glutamate potentiates the toxicity of mutant Cu/Zn-superoxide dismutase in motor neurons by postsynaptic calcium-dependent mechanisms. J Neurosci 1998;18:9673-84.
28. Hadano S, Hand CK, Osuga H, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001;29:166-73.
29. Yang Y, Hentati A, Deng HX, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001;29:160-5.
30. Eymard-Pierre E, Lesca G, Dollet S, et al. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet 2002;71:518-27.
31. Devon RS, Helm JR, Rouleau GA, et al. The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. Clin Genet 2003;64:210-15.
32. Gros-Louis F, Meijer IA, Hand CK, et al. An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Ann Neurol 2003;53:144-5.
33. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science 2001;294:1299-304.
34. Yamanaka K, Vande Velde C, Eymard-Pierre E, et al. Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease. Proc Natl Acad Sci USA 2003;100:16041-6.
35. Otomo A, Hadano S, Okada T, et al. ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. Hum Mol Genet 2003;12:1671-87.
36. Kunita R, Otomo A, Mizumura H, et al. Homo-oligomerization of ALS2 through its unique carboxyl-terminal regions is essential for the ALS2-associated Rab5 guanine nucleotide exchange activity and its regulatory function on endosome trafficking. J Biol Chem 2004;279:38626-35.
37. Kris J, Millecamps S, Zhu Q, et al. Creation of a mouse model for juvenile amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(suppl 1):11.
38. Cai H, Wen H, Chaing HC, et al. Physiological role of ALS2: selective vulnerability and generation of ALS2 knockout mice. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(suppl 1):11-12.
39. Kanekura K, Hashimoto Y, Niikura T, et al. Alsin, the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants. J Biol Chem 2004;279:19247-56.
40. Chen YZ, Bennett CL, Huynh HM, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004;74:1128-35.
41. Moreira MC, Klur S, Watanabe M, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 2004;36:225-7.
42. Nishimura AL, Mitne-Neto M, Silva HC, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004;75:822-31.
43. Puis I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003;33:455-6.
44. LaMonte BH, Wallace KE, Holloway BA, et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002;34:715-27.
45. Hosler BA, Siddique T, Sapp PC, et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000;284:1664-9.
46. Ostojic J, Axelman K, Lannfelt L, et al. No evidence of linkage to chromosome 9q21-22 in a Swedish family with frontotemporal dementia and amyotrophic lateral sclerosis. Neurosci Left 2003;340:245-7.
47. Clark LN, Poorkaj P, Wszolek Z, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA 1998;95:13103-7.
48. Mutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5.
49. Kowalska A, Konagaya M, Sakai M, et al. Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex-tauopathy without mutations in the tau gene? Folia Neuropathol 2003;41:59-64.
50. Wilhelmsen KC, Forman MS, Rosen HJ, et al. 17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions. Arch Neurol 2004;61:398-406.
51. Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994;3:1757-61.
52. Tomkins J, Usher P, Slade JY, et al. Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). Neuroreport 1998;9:3967-70.
53. Al-Chalabi A, Enayat ZE, Bakker MC, et al. Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Lancet 1996;347:159-60.
54. Drory VE, Birnbaum M, Korczyn AD, et al. Association of APOE epsilon4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci 2001;190:17-20.
55. Comi GP, Bordoni A, Salani S, et al. Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann Neurol 1998;43:110-16.
56. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
57. Rao SD, Yin HZ, Weiss JH. Disruption of glial glutamate transport by reactive oxygen species produced in motor neurons. J Neurosci 2003;23:2627-33.
58. Fray AE, Ince PG, Banner SJ, et al. The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study. Eur J Neurosci 1998;10:2481-9.
59. Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998;20:589-602.
60. Meyer T, Fromm A, Munch C, et al. The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J Neurol Sci 1999;170:45-50.
61. Flowers JM, Powell JF, Leigh PN, et al. Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. Ann Neurol 2001;49:643-9.
62. Trotti D, Aoki M, Pasinelli P, et al. Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity. J Biol Chem 2001;276:576-82.
63. Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004;427:801.
64. Jackson M, Morrison KE, Al-Chalabi A, et al. Analysis of chromosome 5 q13 genes in ALS: homozygous NAIP deletion in a sporadic case. Ann Neurol 1996;39:796-800.
65. Orrell RW, Habgood JJ, de Belleroche JS, et al. The relationship of spinal muscular atrophy to motor neuron disease: investigation of SMN and NAIP gene deletions in sporadic and familial amyotrophic lateral sclerosis. J Neurol Sci 1997;145:55-61.
66. Veldink JH, van den Berg LH, Cobben JM, et al. Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology 2001;56:749-52.
67. Corcia P, Mayeux-Portas V, Khoris J, et al. Abnormal SMNI gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Ann Neurol 2002;51:243-6.
68. Giess R, Holtmann B, Braga M, et al. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am J Hum Genet 2002;70:1277-86.
69. Brockington A, Lewis C, Wharton S, et al. Vascular endothelial growth factor and the nervous system. Neuropathol Appl Neurobiol 2004;30:427-46.
70. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-94.
71. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8.
72. Brockington A, Kirby J, Eggitt D, et al. Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis. Neurogenetics, 2005, March 18 [Epub ahead of print].
73. Gros-Louis F, Laurent S, Lopes AA, et al. Absence of mutations in the hypoxia response element of VEGF in ALS. Muscle Nerve 2003;28:774-5.
74. Shaw PJ, Ince PG, Falkous G, et al. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 1995;38:691-5.
75. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-74.
76. Smith RG, Henry YK, Mattson MP, et al. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1998;44:696-9.
77. Tohgi H, Abe T, Yamazaki K, et al. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1999;46:129-31.
78. Aguirre T, Van Den Bosch L, Goetschalckx K, et al. Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress. Ann Neurol 1998;43:452-7.
79. Beckman JS, Carson M, Smith CD, et al. ALS, SOD and peroxynitrite. Nature 1993;364:584.
80. Crow JP, Sampson JB, Zhuang Y, et al. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem 1997;69:1936-44.
81. Estevez AG, Crow JP, Sampson JB, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999;286:2498-500.
82. Wang J, Slunt H, Gonzales V, et al. Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. Hum Mol Genet 2003;12:2753-64.
83. Subramaniam JR, Lyons WE, Liu J, et al. Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading. Nat Neurosci 2002;5:301-7.
84. Facchinetti F, Sasaki M, Cutting FB, et al. Lack of involvement of neuronal nitric oxide synthase in the patnogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. Neuroscience 1999;90:1483-92.
85. Upton-Rice MN, Cudkowicz ME, Mathew RK, et al. Administration of nitric oxide synthase inhibitors does not alter disease course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice. Ann Neurol 1999;45:413-14.
86. Son M, Fathallah-Shaykh HM, Elliott JL. Survival in a transgenic model of FALS is independent of iNOS expression. Ann Neurol 2001;50:273.
87. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 1996;16:4069-79.
88. Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002;26:438-58.
89. Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4:209-16.
90. Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002;193:73-8.
91. Kruman II, Pedersen WA, Springer JE, et al. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp Neurol 1999;160:28-39.
92. Spalloni A, Albo F, Ferrari F, et al. Cu/Zn-superoxide dismutase (GLY93→ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainate-mediated toxicity in motor neurons in culture. Neurobiol Dis 2004;15:340-50.
93. Bendotti C, Tortarolo M, Suchak SK, et al. Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem 2001;79:737-46.
94. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-31.
95. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-57.
96. Beal MF. Mitochondria and the pathogenesis of ALS. Brain 2000;123:1291-2.
97. Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int 2002;40:543-51.
98. Siklos L, Engelhardt J, Harati Y, et al. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 1996;39:203-16.
99. Borthwick GM, Johnson MA, Ince PG, et al. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann Neurol 1999;46:787-90.
100. Dhaliwal GK, Grewal RP. Mitochondrial DNA deletion mutation levels are elevated in ALS brains. Neuroreport 2000;11:2507-9.
101. Wiedemann FR, Manfredi G, Mawrin C, et al. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem 2002;80:616-25.
102. Menzies FM, Cookson MR, Taylor RW, et al. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002;125:1522-33.
103. Fukada K, Zhang F, Vien A, et al. Mitochondrial proteomic analysis of a cell line model of familial amyotrophic lateral sclerosis. Mol Cell Proteomics 2004;3:1211-23.
104. Takeuchi H, Kobayashi Y, Ishigaki S, et al. Mitochondrial localization of mutant superoxide dismutase 1 triggers caspase-dependent cell death in a cellular model of familial amyotrophic lateral sclerosis. J Biol Chem 2002;277:50966-72.
105. Higgins CM, Jung C, Ding H, et al. Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J Neurosci 2002;22:RC215.
106. Jaarsma D, Rognoni F, van Duijn W, et al. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta Neuropathol (Berl) 2001;102:293-305.
107. Jung C, Higgins CM, Xu Z. A quantitative histochemical assay for activities of mitochondrial electron transport chain complexes in mouse spinal cord sections. J Neurosci Methods 2002;114:165-72.
108. Maftiazzi M, D'Aurelio M, Gajewski CD, et al. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem 2002;277:29626-33.
109. Guegan C, Vila M, Rosoklija G, et al. Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 2001;21:6569-76.
110. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-8.
111. Andreassen OA, Ferrante RJ, Klivenyi P, et al. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Ann Neurol 2000;47:447-55.
112. Liu J, Lillo C, Jonsson PA, et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 2004;43:5-17.
113. Pasinelli P, Belford ME, Lennon N, et al. Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 2004;43:19-30.
114. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-50.
115. Xu Z, Cork LC, Griffin JW, et al. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell 1993;73:23-33.
116. Cote F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993;73:35-46.
117. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron 1994;13:975-88.
118. Tu PH, Raju P, Robinson KA, et al. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA 1996;93:3155-60.
119. Zhang B, Tu P, Abtahian F, et al. Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation. J Cell Biol 1997;139:1307-15.
120. Couillard-Despres S, Zhu Q, Wong PC, et al. Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. Proc Natl Acad Sci USA 1998;95:9626-30.
121. Beaulieu JM, Nguyen MD, Julien JP. Late onset of motor neurons in mice overexpressing wild-type peripherin. J Cell Biol 1999;147:531-44.
122. Robertson J, Doroudchi MM, Nguyen MD, et al. A neurotoxic peripherin splice variant in a mouse model of ALS. J Cell Biol 2003;160:939-49.
123. Lariviere RC, Beaulieu JM, Nguyen MD, et al. Peripherin is not a contributing factor to motor neuron disease in a mouse model of amyotrophic lateral sclerosis caused by mutant superoxide dismutase. Neurobiol Dis 2003;13:158-66.
124. Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 1999;2:50-6.
125. Reid E, Kloos M, Ashley-Koch A, et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 2002;71:1189-94.
126. Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1 Bbeta. Cell 2001;105:587-97.
127. Hafezparast M, Klocke R, Ruhrberg C, et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003;300:808-12.
128. Watanabe M, Dykes-Hoberg M, Culotta VC, et al. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 2001;8:933-41.
129. Bruening W, Roy J, Giasson B, et al. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem 1999;72:693-9.
130. Allen S, Heath PR, Kirby J, et al. Analysis of the cytosolic proteome in a cell culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defenses, and nitric oxide synthetic pathways. J Biol Chem 2003;278:6371-83.
131. Johnston JA, Dalton MJ, Gurney ME, et al. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000;97:12571-6.
132. Takeuchi H, Kobayashi Y, Yoshihara T, et al. Hsp70 and Hsp40 improve neurite outgrowth and suppress intracytoplasmic aggregate formation in cultured neuronal cells expressing mutant SOD1. Brain Res 2002;949:11-22.
133. Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-5.
134. Pramatarova A, Laganiere J, Roussel J, et al. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 2001;21:3369-74.
135. Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci 2002;22:4825-32.
136. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003;302:113-17.
137. Gonzalez-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999;22:219-40.
138. Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001;57:1282-9.
139. Kawomota T, Akiyama H, Yamada T, et al. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992;140:691-707.
140. Sekizawa T, Openshaw H, Ohbo K, et al. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 1998;154:194-9.
141. Hensley K, Floyd RA, Gordon B, et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 2002;82:365-74.
142. Aimer G, Teismann P, Stevic Z, et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002;58:1277-9.
143. Elliott JL. Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res Mol Brain Res 2001;95:172-8.
144. Tikka TM, Vartiainen NE, Goldsteins G, et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 2002;125:722-31.
145. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003;53:267-70.
146. Brooks BR, Shodis KA, Lewis DH, et al. Natural history of amyotrophic lateral sclerosis. Quantification of symptoms, signs, strength, and function. Adv Neurol 1995;68:163-84.
147. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 2001;27:257-74.
148. Guegan C, Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest 2003;111:153-61.
149. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999;58:459-71.
150. Mu X, He J, Anderson DW, et al. Altered expression of bcl-2 and box mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann Neurol 1996;40:379-86.
151. Sathasivam S, Grierson AJ, Shaw PJ. Characterisation of the caspase cascade in a cell culture model of SOD1-related FALS: expression, activation and therapeutic effects of inhibition. Neuropath Appl Neurobiol (in press).
152. Li M, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288:335-9.
153. Vukosavic S, Dubois-Dauphin M, Romero N, et al. Bax and Bcl-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999;73:2460-8.
154. Shaw PJ, Eggett CJ. Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J Neurol 2000;247(suppl 1):117-27.
155. Durham HD. Factors underlying the selective vulnerability of motor neurons to neurodegeneration. In: Shaw PJ, Strong MJ, eds. Blue books of practical neurology: motor neuron disorders. Philadelphia: Butterworth Heinemann, 2003:379-400.
156. Williams TL, Day NC, Ince PG, et al. Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1997;42:200-7.
157. Ince P, Stout N, Shaw P, et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol Appl Neurobiol 1993;19:291-9.
158. Batulan ZB, Minotti S, Figlewicz DA, et al. High threshold for activation of the stress response in motor neurons: a source of vulnerability in ALS? Society of Neuroscience Abstracts 2000;26:85.15.
159. Sullivan PG, Rabchevsky AG, Keller JN, et al. Intrinsic differences in brain and spinal cord mitochondria: Implication for therapeutic interventions. J Comp Neurol 2004;474:524-34.
160. Kirby J, Halligan E, Baptista MJ, et al. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain (in press).
161. Olsen MK, Roberds SL, Ellerbrock BR, et al. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol 2001;50:730-40.
162. Heath PR, Tomkins J, Ince PG, et al. Quantitative assessment of AMPA receptor mRNA in human spinal motor neurons isolated by laser capture microdissection. Neuroreport 2002;13:1753-7.
163. Turner MR, Leigh PN. Disease-modifying therapies in motor neuron disorders: the present position and potential future developments. In: Shaw PJ, Strong MJ, eds. Blue books of practical neurology: motor neuron disorders. Philadelphia: Butterworth-Heinemann, 2003:497-544.